TICKERNERD
Menu
CHECHEHealthcare · Medical Care Facilities

CHE Stock Forecast: Chemed Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$533
−0.80% on the day

The 4 Wall Street analysts covering Chemed Corp. hold a median 12-month price target of $549 — +3.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 13 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$7.1B
Ticker Nerd rank
87 / 100
Median analyst target
$549
Analysts covering
4
Total return, dividends reinvested
1W
−3.6%
1M
+8.3%
YTD
+24.9%
1Y
+20.5%
From 52W high
−3.6%
From 52W low
+44.8%
$368
$553
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CHE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Chemed Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
87 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
96
Volatility
91
Quality
84
Accruals
73
Value
67
Momentum
58
Issuance
56
Growth
51
Size
19

Revisions (96): Analysts have, on balance, been raising their forecasts.

Growth (51): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (19): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CHE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CHE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$350$400$450$500$550$600Oct 25Jan 26Apr 26Jul 26CHEHigh $590Median $549Low $520

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
1 Buy3 Hold0 Sell
Low $520Median $549High $590

The green dot is the last close — the median target sits +3.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
31 July 2026OppenheimerMaintainsOutperform$500 → $590
30 July 2026RBC CapitalMaintainsSector Perform$436 → $548
9 July 2026B of A SecuritiesMaintainsNeutral$450 → $510
9 July 2026B of A SecuritiesMaintainsNeutral—
27 Apr 2026RBC CapitalMaintainsSector Perform—
27 Feb 2026OppenheimerMaintainsOutperform—
27 Feb 2026RBC CapitalDowngradeSector Perform—
22 Jan 2026JefferiesDowngradeHold—
10 Nov 2025RBC CapitalMaintainsOutperform—
10 Sept 2025B of A SecuritiesMaintainsBuy—
2 Sept 2025JefferiesUpgradeBuy—
31 July 2025OppenheimerMaintainsOutperform—
31 July 2025RBC CapitalMaintainsOutperform—
25 July 2025JefferiesInitiatesHold—
30 June 2025B of A SecuritiesMaintainsBuy—
30 June 2025RBC CapitalMaintainsOutperform—
28 Apr 2025RBC CapitalMaintainsOutperform—
14 Mar 2025RBC CapitalMaintainsOutperform—
5 Nov 2024RBC CapitalMaintainsOutperform—
21 May 2024RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CHE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CHE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+4.8%
Analysts raising
0
Analysts cutting
1
Fundamentals

Chemed Corp. (CHE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
27.2×

Cheaper than 30% of US stocks

Price / sales
2.7×

Cheaper than 45% of US stocks

Price / book
8.5×

Cheaper than 13% of US stocks

EV / EBITDA
17.4×

Cheaper than 19% of US stocks

Growth & margins
Revenue growth (YoY)
8.8%

Higher than 49% of US stocks

Earnings growth (YoY)
29.0%

Higher than 66% of US stocks

Gross margin
32.8%

Higher than 39% of US stocks

Operating margin
13.3%

Higher than 70% of US stocks

Net margin
10.6%

Higher than 71% of US stocks

Returns & dividend
Return on equity
27.1%

Higher than 86% of US stocks

Return on assets
13.5%

Higher than 96% of US stocks

Dividend yield
0.4%

Higher than 9% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CHE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
CHEChemed Corp.$7.1B
87
PACSPACS Group, Inc.$7.0B
93
ENSGThe Ensign Group, Inc.$10.5B
67
UHSUniversal Health Services, Inc.$10.7B
65
LFSTLifestance Health Group, Inc.$4.7B
96
CONConcentra Group Holdings Parent, Inc.$4.5B
95
DVADaVita, Inc.$12.0B
90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Chemed Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CHE news & analysis

Chemed Corporation Declares Quarterly Dividend of 70 Cents

GlobeNewsWire · 6 Aug 2026positive

Chemed Corporation's board declared a quarterly cash dividend of 70 cents per share, payable September 3, 2026, to shareholders of record as of August 17, 2026. The dividend represents a 10-cent, or 17%, increase over the 60-cent dividend paid in June 2026.

Why it matters — A CHE watcher would note the higher quarterly payout as a sign of the company's ongoing commitment to returning capital to shareholders.

AVAH vs. CHE: Which Stock Should Value Investors Buy Now?

Zacks Investment Research · 5 Aug 2026neutral

Zacks Investment Research published an article comparing Aveanna Healthcare (AVAH) and Chemed (CHE) as value investment opportunities in the Medical - Outpatient and Home Healthcare sector. The piece poses the question of which of the two stocks currently presents the better value opportunity for investors.

Why it matters — A CHE watcher would care because the article places Chemed in a value-focused stock comparison within its home healthcare sector peer group, offering perspective on how the company is viewed by investment researchers.

Chemed Corporation: Why A Spin-Off Could Unlock Its Hidden Value

Seeking Alpha · 5 Aug 2026positive

A Seeking Alpha analyst issued a Buy rating on Chemed Corporation, citing activist pressure for a spin-off that could unlock value by eliminating the conglomerate discount. The report notes VITAS's strong Q2 performance with 8.8% revenue growth and 18.2% Adjusted EBITDA margin, while Roto-Rooter faces margin pressure from rising digital marketing costs.

Why it matters — CHE watchers would care because the spin-off thesis and activist pressure could lead to a major corporate restructuring that may affect the company's valuation and how its two main businesses are perceived by the market.

Why Chemed (CHE) is a Top Momentum Stock for the Long-Term

Zacks Investment Research · 3 Aug 2026positive

Zacks Investment Research identifies Chemed (CHE) as a top momentum stock for the long-term, highlighting its favorable position based on the Zacks Style Scores. The article points to CHE's strong momentum characteristics among top-rated stocks.

Why it matters — A Chemed watcher would care because Zacks' positive momentum assessment provides an indicator of how the stock ranks among top-rated stocks by investing style.

Chemed Q2 Earnings Call Highlights

MarketBeat · 29 July 2026positive

Chemed reported Q2 2026 results with VITAS hospice performing better than expected, while Roto-Rooter grew revenue but faced higher customer-acquisition costs.

Why it matters — The outperformance at VITAS, Chemed's largest business, is a key driver of overall company results, though rising costs at Roto-Rooter bear watching.

FAQ

Frequently asked questions about CHE stock

What is the CHE stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Chemed Corp. have a median 12-month price target of $549, with estimates ranging from $520 to $590. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CHE stock a buy right now?

Of the 4 analysts covering Chemed Corp., 1 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Chemed Corp. 87 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CHE?

As at 13 Aug 2026, Chemed Corp. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (96 of 100).

Will CHE stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +3.0% from the last close, and Ticker Nerd's factor model ranks Chemed Corp. 87 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CHE stock forecast for 2030?

No analyst covering Chemed Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CHE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $520 to $590 over the next 12 months.

How has CHE stock performed over the past year?

Chemed Corp. returned +20.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Chemed Corp. do?

Chemed Corporation operates as a diversified services company through its two primary segments: VITAS Healthcare and Roto-Rooter. VITAS provides hospice and palliative care services to patients across the United States via a comprehensive network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers, focusing on end-of-life care.

What is the latest news on CHE?

The most recent item we track (GlobeNewsWire, 6 Aug 2026): "Chemed Corporation Declares Quarterly Dividend of 70 Cents". Chemed Corporation's board declared a quarterly cash dividend of 70 cents per share, payable September 3, 2026, to shareholders of record as of August 17, 2026. The dividend represents a 10-cent, or 17%, increase over the 60-cent dividend paid in June 2026.

Company

About Chemed Corp.

Chemed Corporation operates as a diversified services company through its two primary segments: VITAS Healthcare and Roto-Rooter. VITAS provides hospice and palliative care services to patients across the United States via a comprehensive network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers, focusing on end-of-life care. Roto-Rooter delivers essential plumbing, drain cleaning, excavation, water restoration, and related maintenance services to both residential and commercial customers through a combination of company-owned branches, independent contractors, and franchisees. This dual-segment structure enables Chemed Corporation to serve distinct yet essential needs in the healthcare and home services markets, offering resilience through non-correlated business lines. Founded in 1970 and headquartered in Cincinnati, Ohio, Chemed Corporation maintains a strong presence in these sectors, supporting communities with critical care and repair solutions.

CEO Mr. Kevin J. McNamara · 15,811 employees · United States · https://www.chemed.com